[1]陈豪,谭志荣,周宏灏.含黄素单氧化酶3(FMO3)结构、功能及其基因多态性的研究进展[J].中国药理学通报,2008,(10):0.
 CHEN Hao,TAN Zhi rong,ZHOU Hong hao.Advance in flavincontaining monooxygenase 3 (FMO3):structure/function and genetic polymorphisms[J].Chinese Pharmacological Bulletin,2008,(10):0.
点击复制

含黄素单氧化酶3(FMO3)结构、功能及其基因多态性的研究进展()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2008年10期
页码:
0
栏目:
讲座与综述
出版日期:
2008-10-25

文章信息/Info

Title:
Advance in flavincontaining monooxygenase 3 (FMO3):structure/function and genetic polymorphisms
作者:
陈豪谭志荣周宏灏
中南大学临床药理研究所,湖南 长沙410078
Author(s):
CHEN HaoTAN ZhirongZHOU Honghao
Institute of Clinical Pharmacology,Central South University,Changsha410078,China
关键词:
FMO3基因多态性药物代谢个体化治疗
Keywords:
flavincontaining monooxygenase 3genetic polymorphismdrug metabolismindividual treatment
分类号:
R05;R 34549
文献标志码:
A
摘要:
含黄素单氧化酶3(flavincontaining monooxygenase 3,FMO3)是一种重要的肝微粒体酶,参与体内大量药物、外源性物质和其他一些化学物质的氧化代谢。FMO3基因存在多态性,其中的一些基因突变可以引起酶活性改变,从而改变底物的代谢。体内外许多研究证明FMO3有明显的个体差异和种族差异,因此,FMO3的遗传变异在药物研制和个体化治疗中将起着重要的作用。该文就FMO3结构、功能及其基因多态性与药物代谢和疾病的关系进行综述。
Abstract:
Flavincontaining monooxygenase 3 (FMO3) is an important hepatic microsomal enzyme that oxidizes a number of drugs,xenobiotics and other chemicals.Many variants in the gene encoding FMO3 have been identified,some of which result in altered enzymatic activity,consenquently,altered substrate metabolism.Studies also implicate individual and ethnic differences in FMO3.Thus,it is anticipated that knowledge regarding functionallyrelevant FMO3 genetic variability will become increasingly important for drug development and patient therapeutic choices.

参考文献/References:

[1]Phillips I R,Dolphin C T,Clair P,et al.The molecular biology of the flavincontaining monooxygenases of man[J].Chem Biol Interact,1995,96(1):17-32.
[2]Koukouritaki S B,Simpson P,Yeung C K,et al.Human hepatic flavincontaining monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression[J].Pediatr Res,2002,51(2):236-43.
[3]AlWaiz M,Ayesh R,Mitchell S C,et al.A genetic polymorphism of the Noxidation of trimethylamine in humans[J].Clin Pharmacol Ther,1987,42(5):588-94.
[4]Chung W G,Park C S,Roh H K,et al.Oxidation of ranitidine by isozymes of flavincontaining monooxygenase and cytochrome P450[J].Jpn J Pharmacol,2000,84(2):213-20.
[5]Lawton M P,Gasser R,Tynes R E,et al.The flavincontaining monooxygenase enzymes expressed in rabbit liver and lung are products of related but distinctly different genes[J].J Biol Chem,1990,265(10):5855-61.
[6]Massey V.Activation of molecular oxygen by flavins and flavoproteins[J].J Biol Chem,1994,269(36):22459-62.
[7]郭喻,汪晖.人细胞色素P450同工酶探针底物特异性的研究进展[J].中国药理学通报,2007,23(7):851-4.
[7]Guo Y,Wang H.Study of probe substrate specificity for human cytochrome P450 isoenzymes[J].Chin Pharmacol Bull,2007,23(7):851-4.
[8]Mitchell S C,Smith R L.Trimethylaminuria:the fish malodor syndrome[J].Drug Metab Dispos,2001,29(4 Pt 2):517-21.
[9]Park C S,Chung W G,Kang J H,et al.Phenotyping of flavincontaining monooxygenase using caffeine metabolism and genotyping of FMO3 gene in a Korean population[J].Pharmacogenetics,1999,9(2):155-64.
[10]Lang D H,Rettie A E.In vitro evaluation of potential in vivo probes for human flavincontaining monooxygenase (FMO):metabolism of benzydamine and caffeine by FMO and P450 isoforms[J].Br J Clin Pharmacol,2000,50(4):311-4.
[11]Kang J H,Chung W G,Lee K H,et al.Phenotypes of flavincontaining monooxygenase activity determined by ranitidine Noxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population[J].Pharmacogenetics,2000,10(1):67-78.
[12]Stormer E,Roots I,Brockmoller J. Benzydamine Noxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity[J].Br J Clin Pharmacol,2000,50(6):553-61.
[13]Lattard V,Zhang J,Tran Q,et al.Two new polymorphisms of the FMO3 gene in Caucasian and AfricanAmerican populations:comparative genetic and functional studies[J].Drug Metab Dispos,2003,31(7):854-60.
[14]Cashman J R,Zhang J,Leushner J,et al.Population distribution of human flavincontaining monooxygenase form 3:gene polymorphisms[J].Drug Metab Dispos,2001,29(12):1629-37.
[15]Koukouritaki S B,Hines R N.Flavincontaining monooxygenase genetic polymorphism:impact on chemical metabolism and drug development[J].Pharmacogenomics,2005,6(8):807-22.
[16]Koukouritaki S B,Poch M T,Cabacungan E T,et al.Discovery of novel flavincontaining monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants[J].Mol Pharmacol,2005,68(2):383-92.
[17]Furnes B,Feng J,Sommer S S,et al.Identification of novel variants of the flavincontaining monooxygenase gene family in African Americans[J].Drug Metab Dispos,2003,31(2):187-93.
[18]Brunelle A,Bi Y A,Lin J,et al.Characterization of two human flavincontaining monooxygenase (form 3) enzymes expressed in Escherichia coli as maltose binding protein fusions[J].Drug Metab Dispos,1997,25(8):1001-7.
[19]Treacy E P,Akerman B R,Chow L M,et al.Mutations of the flavincontaining monooxygenase gene (FMO3) cause trimethylaminuria,a defect in detoxication[J].Hum Mol Genet,1998,7(5):839-45.
[20]Dolphin C T,Janmohamed A,Smith R L,et al.Missense mutation in flavincontaining monooxygenase 3 gene,FMO3,underlies fishodour syndrome[J].Nat Genet,1997,17(4):491-4.
[21]Cashman J R,Akerman B R,Forrest S M,et al.Populationspecific polymorphisms of the human FMO3 gene:significance for detoxication[J].Drug Metab Dispos,2000,28(2):169-73.
[22]Dolphin C T,Janmohamed A,Smith R L,et al.Compound heterozygosity for missense mutations in the flavincontaining monooxygenase 3 (FM03) gene in patients with fishodour syndrome[J].Pharmacogenetics,2000,10(9):799-807.
[23]Zschocke J,Kohlmueller D,Quak E,et al.Mild trimethylaminuria caused by common variants in FMO3 gene[J].Lancet,1999,354(9181):834-5.
[24]Sachse C,Ruschen S,Dettling M,et al.Flavin monooxygenase 3 (FMO3) polymorphism in a white population:allele frequencies,mutation linkage,and functional effects on clozapine and caffeine metabolism[J].Clin Pharmacol Ther,1999,66(4):431-8.
[25]Lambert D M,Mamer O A,Akerman B R,et al.In vivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene[J].Mol Genet Metab,2001,73(3):224-9.
[26]Hisamuddin I M,Wehbi M A,Chao A,et al.Genetic polymorphisms of human flavin monooxygenase 3 in sulindacmediated primary chemoprevention of familial adenomatous polyposis[J].Clin Cancer Res,2004,10(24):8357-62.
[27]Humbert J A,Hammond K B,Hathaway W E.Trimethylaminuria:the fishodour syndrome[J].Lancet,1970,2(7676):770-1.

相似文献/References:

[1]马晶晶,李金恒,曹晓梅,等.基因多态性对奥美拉唑药动学与相对生物利用度的影响[J].中国药理学通报,2010,(02):258.
 MA Jing jing,LI Jin heng,CAO Xiao mei,et al.Effects of CYP2C19 polymorphism on pharmacokinetic profile and comparative bioavailability of omeprazole[J].Chinese Pharmacological Bulletin,2010,(10):258.
[2]杨静,乔海灵.过敏反应与HLA基因多态性[J].中国药理学通报,2008,(04):0.
 YANG Jing,QIAO Hai Ling.Correlation between allergy and HLA genetic polymorphism[J].Chinese Pharmacological Bulletin,2008,(10):0.
[3]杨静,乔海灵.青霉素特异性IgE抗体的种类与HLADRB基因多态性[J].中国药理学通报,2008,(06):0.
 YANG Jing,QIAO Hai ling.Correlation of HLADRB genetic locus with penicillinspecific IgE antibodies[J].Chinese Pharmacological Bulletin,2008,(10):0.
[4]余敏,周宏灏,刘昭前.糖尿病肾病相关基因研究进展[J].中国药理学通报,2008,(11):0.
 YU Min,ZHOU Hong hao,LIU Zhao qian.Progress in related genes of diabetic nephropathy[J].Chinese Pharmacological Bulletin,2008,(10):0.
[5]李慧华,杨敏,余敏,等.β3AR Trp64Arg遗传多态性对T2DM患者罗格列酮疗效的影响[J].中国药理学通报,2009,(03):0.
 LI Hui hua,YANG Min,YU Min,et al.The effect of β3AR Trp64Arg on rosiglitazone response in T2DM patients[J].Chinese Pharmacological Bulletin,2009,(10):0.
[6]吴培培,李奕,杨飞,等.抗癫痫药物等引发药疹与人类白细胞抗原基因的相关性研究[J].中国药理学通报,2013,(01):113.
 WU Pei pei,LI Yi,YANG Fei,et al.Druginduced cADR and polymorphism of HLA genes:A correlational study[J].Chinese Pharmacological Bulletin,2013,(10):113.
[7]彭娟,谭胜蓝,周宏灏,等.华法林药物基因组学和个体化用药[J].中国药理学通报,2013,(02):169.
 PENG Juan,TAN Sheng lan,ZHOU Hong Hao,et al.Pharmacogenomics of warfarin and its personalized treatment[J].Chinese Pharmacological Bulletin,2013,(10):169.
[8]李璐,王明霞,赵宝华.细胞色素P450 2D6、3A4和19A1基因多态性与乳腺癌的药物治疗[J].中国药理学通报,2013,(03):311.
 LI Lu,WANG Ming xia,ZHAO Bao hua.Cytochrome P450 2D6, 3A4 and 19A1:gene polymorphism and drug therapy of breast cancer[J].Chinese Pharmacological Bulletin,2013,(10):311.
[9]邵倩,班博,施锦绣.SUR1和KCNJ11基因多态性与磺脲类药物继发性失效的相关性研究[J].中国药理学通报,2013,(07):927.
 SHAO Qian,BAN Bo,SHI Jin xiu.Relations of SUR1 and KCNJ11 gene polymorphisms with secondary failure of sulfonylurea in type 2 diabetes[J].Chinese Pharmacological Bulletin,2013,(10):927.
[10]李江峰,闫良,王晓飞,等.高脂饮食及ABCB1基因多态性对硝苯地平 在健康受试者体内药动学的影响[J].中国药理学通报,2014,(04):566.
 LI Jiang-feng,YAN Liang,WANG Xiao-fei,et al.Effect of high-fat meal and ABCB1 C3435T polymorphism onpharmacokinetics of nifedipine in healthy Chinese subjects[J].Chinese Pharmacological Bulletin,2014,(10):566.

备注/Memo

备注/Memo:
收稿日期:2008-04-22,修回日期:2008-07-25:国家自然科学基金资助项目(No 30572226)作者简介:陈豪(1982-),男,硕士,研究方向:临床药理学和遗传药理学,Tel:07314805380,Email:hao102237@sohu.com;周宏灏(1939-),男,中国工程院院士,博士生导师,研究方向:临床药理学和遗传药理学,通讯作者,Tel:07314805379,Email:hhzhou2003@163.com
更新日期/Last Update: 2008-10-15